Breaking News Instant updates and real-time market news.

LH

LabCorp

$175.31

-0.27 (-0.15%)

, DGX

Quest Diagnostics

$100.89

-0.34 (-0.34%)

08:25
05/25/18
05/25
08:25
05/25/18
08:25

UnitedHealth news positive for Quest, 'clearing event' for LabCorp, says Craig-Hallum

Craig-Hallum analyst Kevin Ellich commented on last night's announcements by UnitedHealth (UNH) of long-term strategic partnerships with Quest Diagnostics (DGX) and LabCorp (LH) starting January 1, 2019, whereby both labs will be national providers of lab services. In a research note to investors, Ellich said he is "not surprised" by the announcement, adding that it is "clearly a positive" for Quest, as with UnitedHealth's 48M+ covered lives, it will have access to 90% of all insured lives nationally. Conversely, Kevin sees it as a "clearing event" for LabCorp shares, as the exclusive UnitedHealth contract, which was set to expire at the end of this year, was an overhang. In the event LabCorp loses some UnitedHealth volume, he expects the company will be able to mitigate the impact in a variety of ways, including entry into the Aetna (AET) contract and access to its ~22M medical members, which is exclusive to Quest now but in 2019 Aetna has the option to add another preferred lab provider. Ellich has a Buy rating and $204 price target on LabCorp, while he has a Hold rating and $107 price target on Quest Diagnostics.

LH

LabCorp

$175.31

-0.27 (-0.15%)

DGX

Quest Diagnostics

$100.89

-0.34 (-0.34%)

UNH

UnitedHealth

$242.73

-1.48 (-0.61%)

AET

Aetna

$177.05

-0.31 (-0.17%)

  • 30

    May

  • 12

    Jun

LH LabCorp
$175.31

-0.27 (-0.15%)

05/01/18
05/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Owens Corning (OC) upgraded to Buy from Neutral at Nomura Instinet with analyst Michael Wood saying the current valuation reflects the cyclical downturn while an extended recovery could bring compelling upside. 2. Qorvo (QRVO) upgraded to Overweight from Equal Weight at Barclays with analyst Blayne Curtis saying he sees content gains at Apple (AAPL) being a positive catalyst for the shares. 3. LabCorp (LH) and Quest Diagnostics (DGX) were upgraded to Outperform from Neutral at Baird. 4. Fox Factory (FOXF) upgraded to Buy from Neutral at BofA/Merrill with analyst Rafe Jadrosich saying valuation is attractive following the pullback. 5. Marriott Vacations (VAC) upgraded to Buy from Hold at SunTrust with analyst C. Patrick Scholes saying the 10% stock pullback yesterday was the result of higher expectations for deal synergies, "arb" pressure, sell-on-news factors, as well as limited management commentary regarding revenue synergies on its call. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/16/18
PIPR
05/16/18
NO CHANGE
PIPR
Piper survey shows growth in non-invasive prenatal test volumes
Piper Jaffray analyst William Quirk says his firm's annual survey of obstetricians and gynecologists suggests "significant" near-term growth in average-risk non-invasive prenatal test volume. This is good for Quest Diagnostics (DGX), Illumina (ILMN), LabCorp (LH), Natera (NTRA) and Roche (RHHBY), Quirk tells investors in a research note. Piper found that the number of doctors offering non-invasive prenatal tests to average risk patients increased to 59% in 2018 from 35% last year. Lack of reimbursement remains a barrier to more testing, but importantly, for the second year in a row, resistance to offering NIPT due to Medicaid and clinical data declined, Quirk adds.
05/25/18
MZHO
05/25/18
NO CHANGE
MZHO
Buy
Quest becomes in-network lab for UnitedHealth, says Mizuho
Mizuho analyst Ann Hynes reiterates a Buy rating on Quest Diagnostics (DGX) and Neutral rating on LabCorp (LH) after UnitedHealth (UNH) announced that both companies will participate as national providers of laboratory services for the company effective January 1, 2019. LabCorp will lose its national exclusivity, but remains in-network, as UnitedHealth's national laboratory provider while Quest will be in-network for all plan participants beginning January 1, Hynes tells investors in a research note. She believes the move will enable Quest to reach the high-end of its previously provided long-term outlook range. For LabCorp, the news is disappointing but likely expected and now an overhang has been removed, Haynes contends.
05/25/18
LEHM
05/25/18
NO CHANGE
Target $220
LEHM
Overweight
Barclays boosts price targets for LabCorp, Quest Diagnostics
Barclays analyst Jack Meehan raised his price target for Overweight-rated LabCorp (LH) to $220 from $210 and Equal Weight-rated Quest Diagnostics (DGX) to $120 from $111 after both labs announced a long-term strategic partnership with UnitedHealth (UNH). The insurer opening their contract to let Quest back in was the base case outcome that investors have been expecting, though confirmation removes any uncertainty, Meehan tells investors in a research note. The analyst continues to believe it is also likely that Aetna (AET) will open up network access to LabCorp starting in 2019. He feels an announcement could be imminent. Meehan thinks it would be a "major strategic positive" for LabCorp and Quest if both national payors open their contracts to both national labs.
DGX Quest Diagnostics
$100.89

-0.34 (-0.34%)

UNH UnitedHealth
$242.73

-1.48 (-0.61%)

04/18/18
FBCO
04/18/18
NO CHANGE
Target $270
FBCO
Outperform
UnitedHealth price target raised to $270 from $260 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for UnitedHealth to $270 from $260 following quarterly results. The analyst reiterates an Outperform rating on the shares.
05/22/18
PIPR
05/22/18
NO CHANGE
Target $134
PIPR
Overweight
Centene received intent to award in Iowa, says Piper Jaffray
Piper Jaffray analyst Sarah James says Centene (CNC) yesterday received an intent to award in Iowa, a $1.5B, 600,000 member Medicaid contract currently held by UnitedHealth (UNH) and Anthem (ANTM). While Iowa insurers have faced issues with rates in the past, the state has taken steps to return the contract to profitability, James tells investors in a research note. She estimates Centene could add up to 100,000 members in Iowa, generating $250M in revenue and 2c of earnings per share, with the contract set to begin July 1, 2019. The analyst keeps an Overweight rating on the shares with a $134 price target.
AET Aetna
$177.05

-0.31 (-0.17%)

05/02/18
CANT
05/02/18
UPGRADE
Target $202
CANT
Overweight
Cantor upgrades Aetna to Overweight on 'compelling' risk/reward
Cantor Fitzgerald analyst Steven Halper last night upgraded Aetna to Overweight from Neutral with a price target of $202. The stock closed yesterday down 75c to $178.71. The analyst views the risk/reward on shares as "more compelling" following the company's Q1 results.
05/02/18
05/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Juniper was (JNPR) upgraded to Buy from Neutral at BofA/Merrill and to Hold from Sell at Deutsche Bank. 2. Aetna (AET) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Steven Halper saying he views the risk/reward on shares as "more compelling" following the company's first quarter results. 3. Freeport McMoRan (FCX) upgraded to Outperform from Neutral at CIBC with analyst Oscar Cabrera saying shares have dropped over 20% following the Q1 report, reflecting a worst-case scenario for the Indonesia scenario. 4. Shutterfly (SFLY) upgraded to Neutral from Sell at Goldman Sachs with analyst Christopher Merwin citing the better than expected Q1 report. 5. CommScope (COMM) upgraded to Outperform from Market Perform at Northland with analyst Tim Savageaux saying he believes the company's unique mix of exposure to Tier 1 carrier investment in both fiber optic and 4G/5G wireless infrastructure offers compelling value following the sharp pullback in shares after only a "fairly modest" cut to its EPS expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/23/18
CANT
05/23/18
NO CHANGE
Target $202
CANT
Overweight
Aetna risk/reward 'remains compelling,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper believes Aetna's risk/reward "remains compelling" with the shares trading 13% below his fundamental-based price target of $202. Excluding the impact of the CVS Health (CVS) merger, Aetna's 2018 is likely to be a transition year until the company's investments and improved Medicare Star ratings pay dividends in 2019, Halper tells investors in a research note. He keeps an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

OHI

Omega Healthcare

$31.86

0.07 (0.22%)

21:21
06/24/18
06/24
21:21
06/24/18
21:21
Downgrade
Omega Healthcare rating change at Wells Fargo »

Omega Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.80

0.51 (0.59%)

20:05
06/24/18
06/24
20:05
06/24/18
20:05
Hot Stocks
MiniMed 670G system real-world data show improved time in range »

Medtronic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

GE

General Electric

$13.05

0.29 (2.27%)

, AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

19:31
06/24/18
06/24
19:31
06/24/18
19:31
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

GE

General Electric

$13.05

0.29 (2.27%)

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

BRK.A

Berkshire Hathaway

$286,859.95

2244.95 (0.79%)

BRK.B

Berkshire Hathaway

$188.89

0.05 (0.03%)

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

CMCSA

Comcast

$33.82

1.02 (3.11%)

CMCSK

Comcast

$0.00

(0.00%)

C

Citi

$67.20

-0.43 (-0.64%)

TWTR

Twitter

$45.90

0.68 (1.50%)

MD

Mednax

$44.99

-0.11 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 26

    Jul

  • 27

    Jul

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

OGE

OGE Energy

$34.95

0.15 (0.43%)

19:25
06/24/18
06/24
19:25
06/24/18
19:25
Downgrade
OGE Energy rating change at Goldman Sachs »

OGE Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Acquired by T

$0.00

(0.00%)

, CMCSA

Comcast

$33.82

1.02 (3.11%)

19:18
06/24/18
06/24
19:18
06/24/18
19:18
Hot Stocks
Box Office Battle: 'Jurassic World: Fallen Kingdom' wins weekend with $150M »

Universal (CMCSA; CMCSK)…

TWX

Acquired by T

$0.00

(0.00%)

CMCSA

Comcast

$33.82

1.02 (3.11%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$50.36

1.15 (2.34%)

FOX

21st Century Fox

$48.28

0.31 (0.65%)

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

LGF.A

Lionsgate

$26.90

0.6 (2.28%)

DIS

Disney

$106.37

0.48 (0.45%)

VIAB

Viacom

$30.27

-0.13 (-0.43%)

VIA

Viacom

$35.70

0.15 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

, BRK.A

Berkshire Hathaway

$286,859.95

2244.95 (0.79%)

18:53
06/24/18
06/24
18:53
06/24/18
18:53
Periodicals
Amazon/Berkshire/JPMorgan venture takes aim at middlemen, Bloomberg says »

The health venture…

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

BRK.A

Berkshire Hathaway

$286,859.95

2244.95 (0.79%)

BRK.B

Berkshire Hathaway

$188.89

0.05 (0.03%)

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 12

    Oct

GE

General Electric

$13.05

0.29 (2.27%)

18:42
06/24/18
06/24
18:42
06/24/18
18:42
Periodicals
General Electric nearing deal to sell industrial engines unit, WSJ says »

General Electric is close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

18:25
06/24/18
06/24
18:25
06/24/18
18:25
Conference/Events
Novo Nordisk to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

ERYP

Erytech Pharma

$0.00

(0.00%)

18:17
06/24/18
06/24
18:17
06/24/18
18:17
Hot Stocks
Erytech Pharma confirms strategic focus of eryaspase on solid tumors »

Erytech Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRX

Lexicon

$13.58

0.51 (3.90%)

18:12
06/24/18
06/24
18:12
06/24/18
18:12
Hot Stocks
Lexicon announces positive 52-week results from Sotagliflozin inTandem1 study »

Lexicon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 22

    Mar

PODD

Insulet

$97.37

0.5697 (0.59%)

18:09
06/24/18
06/24
18:09
06/24/18
18:09
Hot Stocks
Insulet presents positive results for Omnipod Horizon Hybrid Closed-Loop System »

Insulet announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

18:00
06/24/18
06/24
18:00
06/24/18
18:00
Hot Stocks
Real-World data show advantages in people treated with Eli Lilly's Trulicity »

People with type 2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LXRX

Lexicon

$13.58

0.51 (3.90%)

17:56
06/24/18
06/24
17:56
06/24/18
17:56
Hot Stocks
Lexicon announces positive 52-week results from Sotagliflozin inTandem2 study »

Lexicon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 22

    Mar

DGX

Quest Diagnostics

$112.13

0.93 (0.84%)

17:53
06/24/18
06/24
17:53
06/24/18
17:53
Hot Stocks
Employer wellness programs may reduce risk of developing chronic conditions »

Employer wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

17:44
06/24/18
06/24
17:44
06/24/18
17:44
Hot Stocks
New data reinforce potential of Eli Lilly's Ultra Rapid Lispro in diabetes »

Eli Lilly's ultra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

17:38
06/24/18
06/24
17:38
06/24/18
17:38
Hot Stocks
Eli Lilly announces findings from new analyses of EMPA-REG OUTCOME trial »

Boehringer Ingelheim and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

CTRV

ContraVir Pharmaceuticals

$1.47

-0.06 (-3.92%)

17:30
06/24/18
06/24
17:30
06/24/18
17:30
Conference/Events
ContraVir Pharmaceuticals to hold a business news update conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZFGN

Zafgen

$6.94

0.32 (4.83%)

17:27
06/24/18
06/24
17:27
06/24/18
17:27
Hot Stocks
Zafgen announces positive full results in phase 2 clinical trial of ZGN-1061 »

Zafgen announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNKD

MannKind

$1.98

0.02 (1.02%)

17:22
06/24/18
06/24
17:22
06/24/18
17:22
Hot Stocks
MannKind presents positive Afrezza clinical data from STAT, AFFINITY studies »

MannKind announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$61.46

0.295 (0.48%)

16:53
06/24/18
06/24
16:53
06/24/18
16:53
Hot Stocks
Merck presents new data from comparative trials in Type 2 diabetes »

Merck, known as MSD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 10

    Sep

  • 23

    Oct

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

04:55
06/24/18
06/24
04:55
06/24/18
04:55
Conference/Events
Novo Nordisk to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

A

Agilent

$62.79

-0.24 (-0.38%)

, ABT

Abbott

$61.93

0.19 (0.31%)

04:55
06/24/18
06/24
04:55
06/24/18
04:55
Conference/Events
American Diabetes Association to hold a conference »

78th Scientific Sessions…

A

Agilent

$62.79

-0.24 (-0.38%)

ABT

Abbott

$61.93

0.19 (0.31%)

AKCA

Akcea Therapeutics

$26.24

0.4 (1.55%)

AMGN

Amgen

$184.86

-1.14 (-0.61%)

AZN

AstraZeneca

$35.06

-0.095 (-0.27%)

BAYRY

Bayer

$0.00

(0.00%)

CL

Colgate-Palmolive

$64.63

1.15 (1.81%)

DXCM

DexCom

$99.52

-0.2 (-0.20%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

IRWD

Ironwood

$19.35

0.74 (3.98%)

JNJ

Johnson & Johnson

$122.81

1.36 (1.12%)

MDT

Medtronic

$86.80

0.51 (0.59%)

MNKD

MannKind

$1.98

0.02 (1.02%)

WAKE

Wake Forest Bancshares Inc.

$0.00

(0.00%)

VLRX

Valeritas

$1.39

0.035 (2.58%)

TNDM

TNDM

SNY

Sanofi

$39.98

0.96 (2.46%)

SIEGY

Siemens

$0.00

(0.00%)

SENS

Senseonics

$4.76

-0.2 (-4.03%)

REGN

Regeneron

$331.82

2.81 (0.85%)

PODD

Insulet

$97.37

0.5697 (0.59%)

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

MRK

Merck

$61.46

0.295 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 28

    Jun

  • 02

    Jul

  • 06

    Jul

  • 12

    Jul

  • 17

    Jul

  • 18

    Jul

  • 11

    Aug

  • 27

    Aug

  • 30

    Aug

  • 10

    Sep

  • 06

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Jan

  • 22

    Mar

AMGN

Amgen

$184.86

-1.14 (-0.61%)

12:23
06/23/18
06/23
12:23
06/23/18
12:23
Hot Stocks
Amgen's Repatha 'significantly reduced' LDL-C, non-HDL-C in Type 2 diabetes »

Amgen announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

12:18
06/23/18
06/23
12:18
06/23/18
12:18
Hot Stocks
Eli Lilly's Trulicity shows promise in delivering efficacy in type 2 diabetes »

Two investigational doses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

IRWD

Ironwood

$19.35

0.74 (3.98%)

12:14
06/23/18
06/23
12:14
06/23/18
12:14
Hot Stocks
Ironwood announced Praliciguat phase IIa study data »

Ironwood Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.